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In this paper we discuss the consensus view on the use of qualifying biomarkers in drug
safety, raised within the frame of the XXIV meeting of the Spanish Society of Clinical Phar-
macology held in Málaga (Spain) in October, 2011. The widespread use of biomarkers as
surrogate endpoints is a goal that scientists have long been pursuing. Thirty years ago,
when molecular pharmacogenomics evolved, we anticipated that these genetic biomark-
ers would soon obviate the routine use of drug therapies in a way that patients should
adapt to the therapy rather than the opposite. This expected revolution in routine clinical
practice never took place as quickly nor with the intensity as initially expected. The con-
certed action of operating multicenter networks holds great promise for future studies to
identify biomarkers related to drug toxicity and to provide better insight into the underlying
pathogenesis. Today some pharmacogenomic advances are already widely accepted, but
pharmacogenomics still needs further development to elaborate more precise algorithms
and many barriers to implementing individualized medicine exist. We brieﬂy discuss our
view about these barriers and we provide suggestions and areas of focus to advance in
the ﬁeld.
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INTRODUCTION
The widespread use of genetic and non-genetic biomarkers as sur-
rogate endpoints is a goal that scientists have long been pursuing,
aiming to describe risks, exposures, intermediate effects of treat-
ments, and biologic mechanisms. Biomarkers are measurements
that indicate biological processes, and can be used in clinical
practice for disease diagnosis, prognosis, therapy selection, dose
adjustment, and monitoring outcomes. Key issues are the iden-
tiﬁcation of high-risk cohorts and biomarkers that can predict a
response to a particular intervention. Whereas a clinical endpoint
is a characteristic or variable that reﬂects how a patient feels, func-
tions,or survives BiomarkersDeﬁnitionsWorkingGroup (2001), a
surrogate endpoint is a biomarker that is intended to substitute for
a clinical endpoint. That is, a characteristic that is objectively mea-
sured and evaluated as an indicator of normal biologic processes,
pathogenic processes, or pharmacologic responses to a therapeu-
tic intervention (Biomarkers Deﬁnitions Working Group, 2001).
These biomarkers are expected to predict the clinical response
based on epidemiological, therapeutical, pathophysiological, or
other scientiﬁc evidence. In relation to its linkage to efﬁcacy or
safety outcomes, three forms of biomarkers can be deﬁned: a tar-
get biomarker measures physical or biological interactions with the
molecular target; these target biomarkers are usually part of the
“proof of mechanism” in drug development. A second type of bio-
markers, deﬁned as mechanism biomarkers, measures a biological
effect presumed to be downstream of the target. Finally, outcome
biomarkers substitute for a clinical outcome or predict an outcome
of a disease or toxicity following treatment. Biomarkers can be of
ﬁve types: physiological measurements, blood tests or other chem-
ical analyses of tissue or bodily ﬂuids, genetic data,metabolic data,
and measurements obtained from images (Institute of Medicine,
2011).
In recent years the developments in genetic biomarkers have
moved from studying the genome sequence and structure to
assessing interindividual variability and trying to understand how
genetic biomarkers relate with the pathophysiology of human dis-
eases and the outcome of drug therapies, particularly in drug
efﬁcacy and toxicity. The development of these genetic biomarkers
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to stratify patient populations (patient selection biomarkers) into
those who should or should not receive a given drug has been
extensively investigated in recent years, and is one of the main
instruments of “personalized medicine” (PHG Foundation, 2010;
Green andGuyer, 2011). Nevertheless until now only a small num-
ber of biomarkers are being used routinely in clinical practice.
Several barriers to implementing the use of these biomarkers exist
(see Table 1 for some examples). Some of these barriers will be dis-
cussed below.We should note that biomarker qualiﬁcation has not
been covered in any International Conference of Harmonization
(ICH) guideline except for the genomic biomarkers (European
Medicines Agency, 2009). Initiatives such as the safer and faster
evidence-based translation (SAFE-T) or the cooperative research
thematic network on adverse reactions to allergens and drugs in
Spain (RIRAAF), which focus on both genetic and non-genetic
biomarkers, were designed to provide robust markers on drug
safety.
The use of biomarkers requires a wide consensus and the devel-
opment of adequate guidelines of its use and implementation.
This manuscript summarizes the view of the participants regard-
ing barriers to implementing the use of biomarkers in clinical
practice, as well as suggestions and areas of focus. This consensus
view was elaborated within the frame of the roundtable of Bio-
markers in the XXIV meeting of the Spanish Society of Clinical
Pharmacology held in Málaga (Spain) in October, 2011. Details
Table 1 | Examples of barriers to implementing individualized
medicine.
BARRIERS DISCUSSED INTHIS PAPER
Need for demonstration of clinical validity and utility
Need for clear guidelines for the use of biomarkers in clinical medicine
Insufﬁcient development of processes and protocols required to translate
biomarker information to clinical practice
• Need for more precise algorithms
• Implementing pharmacogenomics with other “omics”
• Use of surrogate tag-SNPs
• The need of implementation of gene/drug pairs
The need for speciﬁc biomarkers for severe ADRs
Concerns about test costs
The need for the identiﬁcation of new biomarkers
BARRIERS DISCUSSED ELSEWHERE
Fragmentation of health-care systems
Low use of electronic medical records
Health-care systems do not reward the prevention of ADRs
Insufﬁcient awareness about genomics among clinicians
Little genetic testing is done preemptively
Lack of a clear assessment of ethical, legal, and social implication of
biomarker testing
These examples may not apply to all countries. For instance, in some countries
electronic records may be under-utilized or not existing. In other countries the
use of electronic records is compulsory in public health assistance.
Compiled from this study and other studies published elsewhere (Deverka et al.,
2007; Haga and Burke, 2008; Agundez et al., 2009; Relling et al., 2010; Matheis
et al., 2011; Relling and Klein, 2011).
about the meeting, program, and participants can be accessed in
the webpage1.
USE OF BIOMARKERS IN THE ASSESSMENT OF ADVERSE
DRUG REACTIONS
Serious adverse effects are a major challenge in current drug treat-
ment and a major cause for drug withdrawal from the pharma-
ceutical market. Insufﬁcient development of speciﬁc biomarkers
makes causality assessment challenging, is a barrier for the predic-
tion of susceptible patients and hurdles the development of safer
new drugs. Thirty years ago, when molecular pharmacogenomics
evolved, we shared the hope that these genetic biomarkers would
soon allow the routine use of drug therapies adapted to every
patient and to every condition. This expected transformation in
routine clinical practice never came about neither as quickly nor
with the intensity as initially expected.
The conversion of genomic data into clinically useful informa-
tion on how individuals vary in their response to drugs (that is, the
demonstration of clinical validity and utility) still needs further
development (Lesko et al., 2010). Thiopurine methyltransferase
(TPMT) is a good example of this. Whereas a strong pheno-
type/genotype association exists for TPTM (Ford et al., 2009)
most of the azathioprine/mercaptopurine-induced adverse reac-
tions and the efﬁcacy of therapy are not explained by TPMT gene
polymorphisms (Palmieri et al., 2007). It seems that pharmacoge-
nomics alone is not sufﬁcient to explain all the interindividual
variability in drug response, and in recent years many articles
have been published indicating lack of association between poly-
morphisms in genes coding for drug-metabolizing enzymes and
drugs response, even though these drugs are substrates for the
enzymes encoded by the target genes. From an initial point of
view of pharmacogenomics and adverse drug reactions (ADRs),
alterations in genes coding for drug-metabolizing enzymes would
cause a change in the metabolic capacity resulting in accumulation
(or lower levels) of the drug. These alterations in drug concen-
tration would then change the drug response. This initial view
has turned out to be too naïve for most drugs used in clinical
practice. Many drugs initially thought to be speciﬁc substrates for
an enzyme, actually follow several metabolic pathways (Pachko-
ria et al., 2007). Rapidly increasing evidence indicates that the
term enzyme-speciﬁc to deﬁne a drug should be used cautiously
(Agundez et al., 2009). Moreover,many mutations in genes coding
for drug-metabolizing enzymes are not actually linked to major
changes in enzyme activity.
Recently in the World PGX Summit held in Boston, the ques-
tion of whether we have made signiﬁcant progress or got stuck
with a few examples was proposed (Groenen, 2011). The conclu-
sion suggests that we have been somewhat overoptimistic. Many
predictions have come true, but many years later than predicted
(Groenen, 2011). Today some pharmacogenomic advances are
already widely accepted but the available information is still insuf-
ﬁcient: The Food and DrugAdministration (FDA) has published a
“Table of Pharmacogenomic Biomarkers in Drug Label,” that rec-
ognizes the role of pharmacogenomics in identifying responders
1http://www.sefc2011.com/index.php?m= content&e= 44&catid= 2&PHPSESSID
= 6347f60e702128bceadc3b6d7853ae86
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and non-responders to medications, avoiding adverse events, and
optimizing drug dose (Food and DrugAdministration, 2011). The
Clinical Pharmacogenetics Implementation Consortium (CPIC)
of the National Institutes of Health’s Pharmacogenomics Research
Network2 and the Pharmacogenomics Knowledge Base (Phar-
mGKB)3, as well as other national and international initiatives,
are particularly active in providing guidelines and therapeutic rec-
ommendations based on pharmacogenomic testing (Relling and
Klein, 2011; Swen et al., 2011). Table 2 summarizes some major
gene targets proposed in these initiatives. Although it should be
emphasized that discrepancies among therapeutic recommenda-
tions exist. The development of pharmacogenomic guidelines and
recommendations within the frame of a Spanish consortium is an
ongoing project.
Today we have pharmacogenomic-based recommendations in
clinical practice for a very limited number of drugs (about 1–2%
of drugs on the market). In addition, the discrimination capacity
of pharmacogenomics tests within different categories of patients
is limited. That is, all individuals with the same number of defect
alleles are classiﬁed in a single group, whereas evidences for a large
interindividual variability in the metabolic capacity among indi-
viduals with the same genotype exist. At best, pharmacogenomic-
based recommendations usually fall within one of the following
categories: “no action required; select an alternative drug; reduce
the dose by a determined percentage; or monitor plasma concen-
tration.” For instance, for phenytoin therapy it is recommended
to reduce the maintenance dose by 25 and 50% for individuals
heterozygotes and homozygotes, respectively, for CYP2C9 defect
alleles (Swen et al., 2011). Although this is an improvement on
the pre-pharmacogenomics situation, we should ask ourselves if
classifying patients in three categories, instead of one, is enough
improvement. An additional effort to elaborate more precise algo-
rithms predicting drug response is urgently required. For the
future development of such algorithms it would be necessary to
include many factors besides polymorphisms of genes coding for
drug-metabolizing enzymes. These should include at least factors
related to gene expression and regulation, such as the patient’s
transcriptomics signature, phenome, and metabolic proﬁle with a
given drug including relevant lifestyle and environmental factors
that inﬂuence drug metabolism or drug response.
In the last years it has become relatively common to use
tag-SNPs, many of which do not actually cause any functional
alteration in drug-metabolizing enzymes, as a surrogate marker
for another surrogate marker that is, the single nucleotide poly-
morphism (SNP) which actually causes the alteration in drug
metabolism. The use of these surrogates of surrogates can be of
some use from a practical point of view, for instance, to reduce the
cost of the genetic analyses (Garcia-Closas et al., 2011). However,
the price that we have to pay for this relatively small reduction in
costs (or in time) is a reduction in the predictive capacity of the
biomarkers (Agundez et al., 2008; Selinski et al., 2011). As men-
tioned earlier, increasing the predictive capacity of biomarkers is
one of the major problems that we have to solve to translate the
2http://www.pgrn.org
3http://www.pharmgkb.org
Table 2 | Examples of pharmacogenomic targets with therapeutic
recommendations.
Gene/marker Drug involved
IL28B Boceprevir, peginterferon alfa-2b, telaprevir
5q Chromosome Lenalidomide
ALK Crizotinib
BRAF Vemurafenib
CCR5 Maraviroc
CD30 Brentuximab, vedotin
Cholinesterase gene Mivacurium
CYP1A2 Dexlansoprazole
CYP2C19 Citalopram, clopidogrel, dexlansoprazole, diazepam,
esomeprazole, imipramine, lansoprazole, nelﬁnavir,
omeprazole, pantoprazole, prasugrel, rabeprazole,
sertraline, ticagrelor, voriconazole
CYP2C9 Acenocoumarol, carisoprodol, carvedilol, celecoxib,
ﬂurbiprofen, phenytoin, warfarin
CYP2D6 Amitriptyline, aripiprazole, atomoxetine, cevime-
line, citalopram, clomipramine, clozapine, codeine,
desipramine, desloratadine, dextromethorphan, dox-
epin, ﬂecainide, ﬂuoxetine, galantamine, geﬁtinib,
haloperidol, iloperidone, imipramine, metoprolol,
nortriptyline, oxycodone, paroxetine, perphenazine,
pimozide, propafenone, propranolol, protriptyline,
quinidine, risperidone, tetrabenazine, thioridazine,
timolol, tiotropium, tolterodine, tramadol, trim-
ipramine, venlafaxine, zuclopenthixol
DPD Fluorouracil, capecitabine, tegafur
EGFR Cetuximab, erlotinib, geﬁtinib, panitumumab
ER receptor Fulvestrant, tamoxifen
G6PD Chloroquine, dapsone, rasburicase
Her2/neu Lapatinib, trastuzumab
HLA-B*1502 Carbamazepine
HLA-B*5701 Abacavir
LDL receptor Atorvastatin
NAT1/NAT2 Hydralazine, isoniazid, isosorbide, pyrazinamide,
rifampin
Ph Chromosome Busulfan, dasatinib, nilotinib
PML/RARα Arsenic trioxide, tretinoin
Rh genotype Clomiphene
TPMT Azathioprine, mercaptopurine, thioguanine
UGT1A1 Irinotecan
VKORC1 Acenocoumarol, phenprocoumon
Compiled from (Food and Drug Administration, 2011; Johnson et al., 2011; Relling
et al., 2011; Scott et al., 2011; Swen et al., 2011) and CPIC Gene-Drug Pairs (see
http://www.pharmgkb.org/contributors/consortia/cpic_gene-drug_pairs.jsp).
advances in pharmacogenomics to routine clinical practice. The
new platforms have dramatically reduced the cost of genotyp-
ing and the use of surrogates of surrogates is presently no longer
justiﬁed even in terms of cost–beneﬁt.
The development of speciﬁc biomarkers for severe ADRs such
as idiosyncratic drug-induced liver toxicity is particularly urgent.
As the liver plays a central role in drug metabolism, nearly every
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prescribed medication comes with a potential threat of hepato-
toxicity. Despite being a relatively rare condition drug-induced
liver injury (DILI) can lead to serious health problems, with bear-
ings on public health and during preclinical and clinical drug
development. In fact, DILI remains a signiﬁcant cause of mar-
ket withdrawal of commercialized drugs or adoption of regula-
tory measures despite rigorous preclinical and clinical evaluation
processes. Subsequently, the liver is today the major target organ
for toxicity assessments in the course of drug research and devel-
opment. Despite increasing attention to the impact and pathology
of DILI during the last decade, the underlying mechanism of DILI
development is still mainly undeﬁned, partly due to the lack of
a functional animal model in idiosyncratic hepatotoxicity. How-
ever, it is accepted that genetic variations play an important role
in determining hepatotoxicity susceptibility. Early pharmacoge-
netic studies on DILI were mainly conducted using the candidate
gene approach (CGA),wherebypotential geneswere selectedbased
on the understanding of their cellular role and then analyzed
for putative genetic variation between cases and controls. Many
of these studies, therefore, focused on genes involved in drug
metabolism and excretion. This resulted in ﬁndings of associations
between DILI susceptibility and several polymorphisms in various
genes, such as speciﬁc alleles in manganese superoxide dismutase,
glutathione peroxidase, and glutathione S-transferase that are sig-
niﬁcantly more frequent in DILI patients than in controls and
shared across multiple drugs (Lucena et al., 2008, 2010; Andrade
et al., 2009; Agundez et al., 2011). Genome-wide association stud-
ies (GWAS), and international projects such as encyclopedia of
DNA elements (ENCODE) or the 1000 Genomes project, all still
under way, are providing us with a more thorough picture of
human genetic variability and its relation to drug response. In par-
ticular the introduction of the GWAS methodology has opened up
a new path for DILI studies. Several DILI GWA studies using SNP
arrays have been performed to date focusing on different causal
agents. Interestingly, all of these studies have identiﬁed SNPs with
genome-wide signiﬁcance located in the major histocompatibility
(MHC) region on chromosome 6. In addition, some of the iden-
tiﬁed SNPs appear to be shared between different forms of DILI
and in some cases even between different forms of ADRs, despite
the causal agents being functionally and structurally very differ-
ent (Daly et al., 2009; Lucena et al., 2011b). The fact that most
idiosyncratic DILI cases do not demonstrate clinical features of
hypersensitivity (present only in a 23% of the cases; Singer et al.,
2010; Lucena et al., 2011b) highlights the potential of GWAS to
detect novel targets that may not have been chosen for CGA stud-
ies relying on mechanistic strategies. Nevertheless, it should be
emphasized that the combined use of GWA and CGA studies is
required to achieve a full picture of the genetic factors related to
drug safety. GWAS ﬁndings can at times be difﬁcult to explain in
terms of a plausible biological hypothesis and often are not repli-
cated in further CGAS focusing on the target SNPs detected in the
GWAS. Moreover, GWAS are not adequate to characterize copy
number variations in candidate genes. The current generation of
DNA sequencers produce 12 orders of magnitude more data per
run than the most powerful platform available in 2001, and at a
much lower price (a few thousand vs. several million Euros). It is
therefore expected that the use of the next generation sequencing
technologies could increase the potential of CGAS and provide
more robust associations between variations in candidate genes
identiﬁed in GWAS and the risk of developing DILI and other
severe ADRs.
Besides technical limitations, many factors hamper a faster
development of genetic testing in ADRs. Among these, the lack of
sufﬁcient evidence for cost–efﬁciency is one of the most relevant.
Based on average prices, it appears that the cost of implement-
ing a robust, validated diagnostic test into clinical practice should
not be, in principle, exorbitant. However, we will need to conduct
proper economic evaluation assessments to ﬁnd out how it com-
pares, in terms of cost–efﬁciency, with already existing tests, and
what savings its implementation might bring about. Biomarker-
based innovations, if assessed and implemented properly, should
be a bonus, not an additional burden on health-care budgets.
The need for the identiﬁcation of new biomarkers for drug tox-
icity and response is another key point that should be addressed
in the next years. The SAFE-T initiative proposes a generic quali-
ﬁcation strategy for new translational safety biomarkers to enable
potential new medicines to be evaluated more quickly and safely
in patients. The project, run by a public–private partnership of
pharmaceutical industry, academics, and small–medium enter-
prises, addresses the current lack of sensitive and speciﬁc clin-
ical tests to diagnose and monitor drug-induced injury of the
kidney, liver, and vascular system, which are a major hurdle
in drug development (Matheis et al., 2011). SAFE-T operates
under the framework of the EU Innovative Medicines Initiative
Joint Undertaking (IMI-JU)4. First, potential biomarker candi-
dates for drug-induced injury of the kidney, liver, and vascular
system were evaluated and prioritized for clinical qualiﬁcation.
The biomarkers (proteins, metabolites, RNA), once approved by
regulatory agencies for prediction, diagnosis, and monitoring of
organ injuries in a drug development context, could also be used
for diagnosing renal, hepatic, and vascular diseases in a clinical
setting.
FUTURE DEVELOPMENTS
Three major factors are providing momentum for the devel-
opment of personalized medicine. First, the large variability of
current medicines among patients (both in terms of efﬁcacy and
safety), which entails considerable human and economic costs.
Second, economic pressures ensuing from inefﬁciencies in drug
discovery and development processes, a tripling in pharmaceutical
companies’R&D investments in the last 10 years has not translated
into a signiﬁcant increase in the number of new drug approvals.
Finally, technology, in particular genotyping and sequencing tech-
nologies, have undergone a spectacular transformation in the last
decade becoming much faster, accurate, and, above all accessible
not only to large scientiﬁc consortia,but also to smaller institutions
and research groups.
The concerted action of operating multicenter networks holds
great promise for future studies to identify genetic biomarkers
related to drug toxicity and to provide better insight into the
underlying pathogenesis. Several large networks on ADRs have
4http://www.imi.europa.eu
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been set up around the world, such as the Spanish DILI Reg-
istry, the RIRAAF network, the drug-induced liver injury network
(DILIN) in the US to enhance the identiﬁcation and diagnosis of
DILI cases. Likewise, the International DILI Consortium (IDILIC)
has been initiated to enable the performance of high powered
genetic studies. African, Latin–American, and some other pop-
ulations are under-represented in the studies conducted so far,
but this is expected to change. With this in mind, the Spanish
DILI Registry has recently extended its network into Latin Amer-
ica and created a new branch, the Spanish–Latin DILI Network
(Lucena et al., 2011a). Some international initiatives have set up
consortia to develop sufﬁcient evidence to qualify new predic-
tive safety tests for regulatory use that may improve the safety of
new drugs entering the market (e.g., the Biomarker Consortium5,
Predictive Safety Testing Consortium6, the CPIC7 and the Inter-
national Serious Adverse Event Consortium – iSAEC)8. As part
of the Innovative Medicines Initiative in the European Union, the
SAFE-T consortium9 has compiled a comprehensive clinical pro-
gram to help identifying and qualifying new safety biomarkers for
drug-induced kidney, liver, and vascular injury. It is anticipated
that the biomarker and genomic era will allow us to reﬁne deﬁn-
itions of risk, predict response to a particular intervention, guide
5www.biomarkersconsortium.org
6www.c-path.org/pstc.cfm
7http://www.pharmgkb.org/contributors/consortia/cpic_proﬁle.jsp
8www.saeconsortium.org
9www.imi-safe-t.eu
dose selection, and enhance the beneﬁt–risk proﬁle of approved
medicines.
Future expectations in this area include the development of new
diagnostic tools to improve drug toxicity analysis and to identify
susceptible individuals prior to treatment initiation. This transla-
tional research effort involving genetic and non-genetic markers
will hopefully be incorporated to clinical practice in the near
future. Nevertheless, besides the barriers summarized in Table 1, it
should be kept in mind that health–care providers and large uni-
versity hospitals are necessarily going to play a crucial role in the
widespread implementation of personalized medicine. To do so,
they will have to reassess their organizational models and address
the urgent educational needs of health practitioners (clinicians,
pharmacists, etc., but also managers and decision-makers at the
higher levels) in genomic medicine.
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